Sanuwave CEO awarded options for 24,000 shares
SANUWAVE Health reported that Chief Executive Officer and director Morgan C. Frank received a new stock option grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
SANUWAVE Health reported that Chief Executive Officer and director Morgan C. Frank received a new stock option grant. On 01/30/2026, he was awarded options to purchase 24,000 shares of common stock at an exercise price of $26.96 per share, expiring on 01/30/2031.
The options were granted at no cost on the grant date and will vest in four equal installments on the last day of each quarter during 2026, aligning vesting with the company’s quarterly performance periods.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 24,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Options will vest in four equal installments on the last day of each quarter during 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did SANUWAVE (SNWV) report for Morgan C. Frank?
What are the key terms of Morgan C. Frank’s new SANUWAVE (SNWV) stock options?
How do Morgan C. Frank’s SANUWAVE (SNWV) options vest in 2026?
How many SANUWAVE (SNWV) derivative securities does Morgan C. Frank hold after this grant?
Is Morgan C. Frank’s SANUWAVE (SNWV) option grant a purchase or an award?
What roles does Morgan C. Frank hold at SANUWAVE (SNWV) in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.